Tatva Chintan Pharma Chem Ltd

- No specific mention of any current or planned fundraising through debt or equity in the transcript. - Capital expenditure (capex) planned for FY '26 is around INR 110 crores, implying funding will likely come from internal accruals or existing resources. - No explicit details provided about raising funds externally via debt or equity. - Focus appears to be on organic growth, capacity expansion, and selective capex rather than on external fundraising. - Management has not provided guidance or statements related to new fundraising activities in the disclosed Q1 FY '26 earnings call.

- FY '26 capex plan is about INR 110 crores. - New greenfield facility planned at Jolva to support additional capex for agro intermediate production. - Minor capex under consideration for modifications and automation in semiconductor chemical production to move from pilot to plant scale. - Additional capex expected for expanding electrolyte segment capacity, especially for supercapacitor and hybrid vehicle batteries requiring ultra-dry/ultra-pure handling and closed systems. - Potential further expansions and automation anticipated for semiconductor and electrolyte businesses as volumes grow. - Capex decisions for semiconductor scale-up will depend on successful pilot runs and customer validations. - Overall, capex will support growth in SDA, PASC (Pharma & Agro Specialty Chemicals), semiconductor purity chemicals, and electrolyte battery segments.

- Expecting 20% to 25% growth in revenue for FY 2026 compared to FY 2025. - SDA (Structure Directing Agents) segment revenues anticipated to grow with better margin realization, supported by near full plant capacity utilization. - Electrolyte salts segment projected to contribute roughly 10% to the top line by FY 26-27, with significant volume growth (~200% growth mentioned). - PASC (Pharma & Agro and Specialty Chemicals) segment gaining traction, expected to be a significant revenue contributor in FY 26 and beyond. - Semiconductor segment starting commercialization with full-scale expected by 2029, showing promising long-term potential. - Addressable market in SDA estimated at around 20% currently, with further volume increases planned. - Capacity expansions and new large agro intermediate orders to support next year’s growth. - Overall cautious optimism on export market recovery and demand revival from key customers in coming quarters.

- FY '26 revenue growth guidance: ~25% compared to FY '25. - FY '26 EBITDA margin guidance: ~20%, improving from ~15% in Q1. - Margin expansion expected mainly in H2 of FY '26; exit run rate margin likely higher than 20%. - Electrolyte segment expected to contribute about 10% of revenue by FY '26/'27. - Capex plan for FY '26: approximately INR 110 crores to support growth and new product lines. - R&D spend: around 1-1.5% of revenue (~INR 4-5 crores). - SDA prices believed to have bottomed out; future growth anticipated. - Electrolyte business expected to reach peak revenue of about INR 100 crores at optimal utilization. - Medium-term (FY '27/'28) growth outlook not formally guided; to be discussed offline. - Semiconductor segment commercialization anticipated by 2029 with volumes starting ramp-up around 2027.

- The company has high confidence in order execution with clear visibility of orders till at least December 2025. - Most of the orders are already on hand, ensuring no uncertainty regarding near-term order fulfillment. - Bulk orders in the PASC (Phase Transfer Catalyst) segment are set to commence supplies from early 2026. - New orders and approvals in the electrolyte segment, including batteries for hybrid vehicles, indicate growing demand and commercial traction. - There is clear visibility of significant orders ramping up in Q2 and Q3 of FY '26. - Orders include those for new product launches expected from Q3 FY '26 and beyond. - Large customer contracts are anticipated to start supplying from early 2026, contributing significantly to volume growth.